Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | NISCH | Q9Y2I1 | 3/20 | 0.39 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.36 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.36 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.36 |
| ▸ | ITGAL | P20701 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.34 |
| ▸ | DRD1 | P21728 | 1/20 | 0.34 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CASP6 | P55212 | 1/20 | 0.33 |
| ▸ | RET | P07949 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3072276 | 0.81 | MAOA (0.46) | MAOAMAOBNISCHABCG2ITGB2 | |
| SCHEMBL2597074 | 0.71 | NISCH (0.58) | MAOAMAOBNISCHCA2HPGD | |
| SCHEMBL963837 | 0.69 | NISCH (0.53) | NISCHABCG2ITGB2ICAM1ITGAL | |
| SCHEMBL5728870 | 0.69 | MAOA (0.41) | MAOAMAOBNISCH | |
| SCHEMBL8145740 | 0.69 | AHR (0.50) | CA2HTTSMN1; SMN2 | |
| SCHEMBL29236907 | 0.69 | — | — | |
| SCHEMBL10977242 | 0.69 | CA2 (0.36) | MAOAMAOBNISCHCA2HTT | |
| SCHEMBL4333283 | 0.69 | CA2 (0.45) | MAOAMAOBNISCHCA2HTT | |
| SCHEMBL29061280 | 0.69 | MAOA (0.36) | MAOAMAOBNISCHABCG2ITGB2 | |
| SCHEMBL10980338 | 0.69 | CA2 (0.36) | MAOAMAOBNISCHCA2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108463460-B | Microbiocidal oxadiazole derivatives | 先正达参股股份有限公司 | 2022-10-28 | — | — | CN | claimed |
| US-11259524-B2 | Microbiocidal oxadiazole derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2022-03-01 | — | — | US | claimed |
| US-20210037826-A1 | MICROBIOCIDAL OXADIAZOLE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2021-02-11 | — | — | US | claimed |
| US-10798941-B2 | Microbiocidal oxadiazole derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2020-10-13 | — | — | US | claimed |
| US-20190297892-A1 | MICROBIOCIDAL OXADIAZOLE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2019-10-03 | — | — | US | claimed |
| EP-3400223-A1 | MICROBIOCIDAL OXADIAZOLE DERIVATIVES | Syngenta Participations AG (CH) | 2018-11-14 | — | — | EP | claimed |
| WO-2017118689-A1 | MICROBIOCIDAL OXADIAZOLE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2017-07-13 | — | — | WO | claimed |
| US-9206173-B2 | Heterocyclic compounds for the treatment of stress-related conditions | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-12-08 | — | — | US | claimed |
| EP-2435046-B1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF STRESS-RELATED CONDITIONS | OTSUKA PHARMA CO LTD (JP) | 2013-09-04 | — | — | EP | claimed |
| US-20120065189-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF STRESS-RELATED CONDITIONS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-03-15 | — | — | US | claimed |
| WO-2010137738-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF STRESS-RELATED CONDITIONS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-12-02 | — | — | WO | claimed |
| WO-2008047883-A1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENES FOR TREATMENT OF MENTAL DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-04-24 | — | — | WO | claimed |
| US-4221718-A | Process for preparing bendiocarb of crystalline form A | FISONS LIMITED (GB) | 1980-09-09 | — | — | US | claimed |
| EP-4366733-A1 | TETRAHYDROPYRAZOLOPYRIDINE-ANALOG LIGANDS OF NLRX1 AND USES THEREOF | LANDOS BIOPHARMA, INC. (US) | 2024-05-15 | — | — | EP | disclosed |
| CN-117835980-A | Tetrahydropyrazolopyridine analog ligand of NLRX1 and application thereof | 朗多生物制药股份有限公司 | 2024-04-05 | — | — | CN | disclosed |
| EP-3927427-B1 | LANTHIONINE C-LIKE PROTEIN 2 LIGANDS, CELLS PREPARED THEREWITH, AND THERAPIES USING SAME | NIMMUNE BIOPHARMA INC (US) | 2024-02-07 | — | — | EP | disclosed |
| US-4221718-A | Process for preparing bendiocarb of crystalline form A | FISONS LIMITED (GB) | 1980-09-09 | — | — | US | disclosed |
| US-4212883-A | HERBICIDE, INSECTICIDE, ACARICIDE, NEMATOCIDE, FUNGICIDE | BAYER AKTIENGESELLSCHAFT (DE) | 1980-07-15 | — | — | US | disclosed |
| US-4171372-A | INSECTICIDES, MITICIDES | FISONS LIMITED (GB) | 1979-10-16 | — | — | US | disclosed |
| US-4113876-A | INSECTICIDES, FUNGICIDES, HERBICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1978-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210037826-A1 | MICROBIOCIDAL OXADIAZOLE DERIVATIVES | PRF1, NOX1, ARG1 | MAOA 866/4885MAOB 1078/4885NISCH 2168/4885 |
| US-10798941-B2 | Microbiocidal oxadiazole derivatives | PRF1, NOX1, ARG1 | MAOA 900/4885MAOB 1124/4885NISCH 2277/4885 |
| US-20190297892-A1 | MICROBIOCIDAL OXADIAZOLE DERIVATIVES | PRF1, NOX1, ARG1 | MAOA 900/4885MAOB 1124/4885NISCH 2277/4885 |
| US-11259524-B2 | Microbiocidal oxadiazole derivatives | PRF1, NOX1, ARG1 | MAOA 866/4885MAOB 1078/4885NISCH 2168/4885 |
| US-20120065189-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF STRESS-RELATED CONDITIONS | NR3C1, NR3C2, CRH | MAOA 257/4885MAOB 197/4885NISCH 1328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.